{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-115795","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.651146+00:00","generated_at":"2026-06-08T09:31:05.737531+00:00","sec_items":["3.01","7.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nasdaq grants Jaguar Health additional 180-day grace period to regain $1.00 bid price compliance","bullets":["Nasdaq extended compliance deadline to May 6, 2024; company must close at $1.00+ for 10 consecutive business days.","Second 180-day period follows initial non-compliance notice filed May 12, 2023.","CEO Lisa Conte notes Phase 3 OnTarget trial of Mytesi for chemotherapy-induced overactive bowel; top-line results expected before Thanksgiving 2023.","Investigator-initiated studies for MVID and SBS ongoing, results expected by end of 2023 and into 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-115795","json":"https://secwatch.observer/filing/0001104659-23-115795.json","markdown":"https://secwatch.observer/filing/0001104659-23-115795.md","text":"https://secwatch.observer/filing/0001104659-23-115795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923115795/0001104659-23-115795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923115795/tm2330239d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:31:05.737531+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b24e315459f85b04aaf2e50bcb5d4c27270e58b","claim":"Jaguar Health, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"November 8, 2023, Jaguar Health, Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had been granted an additional 180 days, or until May 6, 2024, to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), based on the Company meeting the continued listing requirement for market value of publ","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923115795/0001104659-23-115795-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}